The presence of angiotensin II receptors in elasmobranchs.
The presence of specific Ang II receptors in membrane fractions was investigated using 125I-labeled homologous Ang II ([Asn1, Pro3, Ile5]Ang II; df Ang II) in Triakis scyllia. Specific binding sites occurred in a variety of tissues, with highest binding in interrenal tissue (17.11 +/- 2.45 fmol Ang II/mg protein) and gill (6.26 +/- 0. 69 fmol Ang II/mg protein) and possible Ang II receptors in rectal gland and other tissues. 125I-[Asn1, Pro3, Ile5]Ang II (10(-10)M) binding to branchial cell membrane fraction (25 microg protein) in 5 mM MgCl2, 125 mM NaCl, 50 mM Tris-HCl, 0.2% bovine serum albumin at 28 degrees (1) is rapid and saturable; (2) increases as a function of membrane concentration and time; and (3) optimally fits to a two-site (high-and low-affinity) model. The equilibrium dissociation constant (0.11 +/- 0.01 nM) and binding site concentration (35.00 +/- 1.16 fmol/mg protein) are similar to those of mammalian and avian vascular Ang II receptors. Bound labeled ligand was not competitively displaced by dogfish Ang I, dogfish C-type natriuretic peptide, bradykinin, or the AT1 receptor antagonist, CV 11974. The AT2 receptor antagonist, CGP 42112, was much less potent at displacing the labeled ligand compared to the unlabeled ligand.
Tierney
M
M
Ocean Research Institute, University of Tokyo, Tokyo, Japan.
Takei
Y
Y
Hazon
N
N
D000804:Angiotensin II / Q000032:analysis / Q000378:metabolism*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects / Q000502:physiology; D001713:Biphenyl Compounds; D001920:Bradykinin / Q000494:pharmacology; D001934:Branchial Region / Q000187:drug effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D018940:Elasmobranchii / Q000378:metabolism*; D007457:Iodine Radioisotopes; D008565:Membrane Proteins / Q000187:drug effects / Q000378:metabolism*; D020098:Natriuretic Peptide, C-Type; D009842:Oligopeptides / Q000494:pharmacology; D011506:Proteins / Q000494:pharmacology; D011869:Radioligand Assay; D011945:Receptors, Angiotensin / Q000187:drug effects / Q000378:metabolism*; D013777:Tetrazoles / Q000494:pharmacology; D013997:Time Factors; D014018:Tissue Distribution
D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D007457:Iodine Radioisotopes; D008565:Membrane Proteins; D009842:Oligopeptides; D011506:Proteins; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D000804:Angiotensin II; C060894:CGP 42112A; D020098:Natriuretic Peptide, C-Type; D009320:Atrial Natriuretic Factor; C081643:candesartan; D001920:Bradykinin